Target and Its Patented Drug(s)

Content Navigation (  All   None )                                      
Target General Information
Patent(s) and the Corresponding Patented Drug(s)
References
Target General Information  Top
Target ID T61657 Target Info
Target Name Retinoic acid receptor beta (RARB)
Synonyms RAR-epsilon; RAR-beta; Nuclear receptor subfamily 1 group B member 2; NR1B2; HBV-activated protein; HAP
Target Type Successful Target
Gene Name RARB
Biochemical Class Nuclear hormone receptor
UniProt ID
RARB_HUMAN
Patent(s) and the Corresponding Patented Drug(s)  Top
World Intellectual Property Organization (WIPO)
Patent ID WO2014113695
Title Methods of Treating Diseases Associated with High Fat Diet and Vitamin A Deficiency Using Retinoic Acid Receptor Agonists.
Abstract This invention relates to pharmaceutical composition and methods of using vitamin A and/or RARB agonist for the treatment or prevention of diseases or conditions associated with high fat diet and/or vitamin deficiency. After smoking, high fat diet is said to be the second most lethal habit, causing 300,000 deaths each year in the U.S. alone. High fat diet leads to many health problems, including obesity, stroke, cancer, high blood pressure, diabetes, osteoarthritis, rheumatoid arthritis, multiple sclerosis, heart disease, and diseases in other organs such as liver and kidney.
Applicant(s) Cornell University
Representative Drug(s) D0M5EC Drug Info N.A. Click to Show More [1]
2 D0PU1L Drug Info N.A. [1]
United States Patent and Trademark Office (USPTO)
Patent ID US20140187504
Title Prevention and Treatment of Inflammatory Conditions.
Representative Drug(s) D0E2AD Drug Info N.A. [1]
References  Top
REF 1 Therapeutic use of selective synthetic ligands for retinoic acid receptors: a patent review.Expert Opin Ther Pat. 2016 Aug;26(8):957-71.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.